Class summary at a glance.

Every drug in the Rifamycin Antibacterial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $1.81Bcombined across class
Total Rx claims: 804K243K unique beneficiaries
Generic mfrs (active): 7across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Rifaximin

Brand: XIFAXAN · 637K Part D claims (CY24) · 179K beneficiaries · First FDA approval: 2004-07-25

Brand-only (no generics) 470 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $1.80B

Class share

99%

of class CY24 spend

View profile →

Rifampin

Brand: Rifadin IV · 167K Part D claims (CY24) · 64K beneficiaries · First FDA approval: 1989-05-25

7 generic mfrs 2 plans require PA Active FDA shortage

Low NADAC$0.625

→

Avg plan cost$0.665

Part D spend $10.7M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.